Celcuity Inc. (NASDAQ:CELC) Given Consensus Recommendation of “Buy” by Analysts

Shares of Celcuity Inc. (NASDAQ:CELC) have received an average rating of “Buy” from the seven research firms that are currently covering the company, Marketbeat Ratings reports. Six analysts have rated the stock with a buy recommendation and one has issued a strong buy recommendation on the company. The average 1-year price objective among brokers that have issued a report on the stock in the last year is $29.17.

A number of research analysts have recently issued reports on CELC shares. HC Wainwright reiterated a “buy” rating and issued a $27.00 price target on shares of Celcuity in a report on Thursday, August 15th. Needham & Company LLC reissued a “buy” rating and set a $23.00 target price on shares of Celcuity in a report on Thursday, August 15th. Leerink Partners assumed coverage on Celcuity in a report on Monday, July 22nd. They set an “outperform” rating and a $29.00 target price for the company. Leerink Partnrs upgraded Celcuity to a “strong-buy” rating in a research report on Monday, July 22nd. Finally, Stifel Nicolaus increased their price objective on Celcuity from $39.00 to $42.00 and gave the stock a “buy” rating in a research report on Monday, October 7th.

Celcuity Trading Up 4.6 %

NASDAQ CELC opened at $15.16 on Friday. The stock has a market cap of $532.13 million, a P/E ratio of -5.45 and a beta of 0.75. The company has a current ratio of 14.95, a quick ratio of 14.95 and a debt-to-equity ratio of 0.54. Celcuity has a 12 month low of $8.62 and a 12 month high of $22.19. The stock’s fifty day moving average price is $15.59 and its 200-day moving average price is $16.55.

Celcuity (NASDAQ:CELC) last released its earnings results on Wednesday, August 14th. The company reported ($0.62) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.71) by $0.09. During the same period in the previous year, the firm posted ($0.66) EPS. As a group, equities analysts forecast that Celcuity will post -2.54 EPS for the current fiscal year.

Hedge Funds Weigh In On Celcuity

A number of hedge funds have recently made changes to their positions in CELC. Perceptive Advisors LLC purchased a new position in shares of Celcuity in the 4th quarter valued at $21,583,000. Baker BROS. Advisors LP grew its holdings in Celcuity by 189.9% during the 1st quarter. Baker BROS. Advisors LP now owns 1,552,478 shares of the company’s stock valued at $33,534,000 after purchasing an additional 1,017,000 shares in the last quarter. Samlyn Capital LLC grew its holdings in Celcuity by 92.4% during the 2nd quarter. Samlyn Capital LLC now owns 1,326,953 shares of the company’s stock valued at $21,735,000 after purchasing an additional 637,190 shares in the last quarter. Healthcare of Ontario Pension Plan Trust Fund acquired a new stake in Celcuity during the 1st quarter valued at $3,545,000. Finally, Driehaus Capital Management LLC grew its holdings in Celcuity by 62.3% during the 2nd quarter. Driehaus Capital Management LLC now owns 204,592 shares of the company’s stock valued at $3,351,000 after purchasing an additional 78,525 shares in the last quarter. Hedge funds and other institutional investors own 63.33% of the company’s stock.

Celcuity Company Profile

Celcuity Inc, a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment.